Details of Drug-Drug Interaction
| Drug General Information (ID: DDIXV7836Q) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Hydrocortisone | Drug Info | Metocurine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiinflammatory Agents | Neuromuscular Blocking Agents | |||||||
| Structure | |||||||||
| Mechanism of Hydrocortisone-Metocurine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Hydrocortisone | Metocurine | |||||||
| Mechanism | Potentiates/attenuates neuromuscular blockade |
Neuromuscular blocking agent Neuronal acetylcholine receptor Antagonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuronal acetylcholine receptor | Structure Sequence | |||||||
| Protein Family | Ligand-gated ion channel (TC 1.A.9) family | ||||||||
| Protein Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible. | ||||||||